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Melatonin prevents cardioprotection induced 
by a multi-cycle ischaemic preconditioning 
protocol in the isolated perfused rat heart
S GENADE, K YTREHUS, A LOCHNER
Summary
The powerful cardioprotective actions of melatonin, the chief 
secretory product of the pineal gland, have been attributed 
largely to its free radical-scavenging properties. Free radicals 
play an important role in the triggering action of ischaemic 
preconditioning, the phenomenon whereby exposure of the 
heart to one or more short episodes of ischaemia leads to 
protection against a subsequent long period of ischaemia. 
The aim of this study was, therefore, to establish whether 
melatonin, in view of its free radical-scavenging ability, 
would affect the beneficial actions of preconditioning. 
Isolated, perfused, working hearts were subjected to 1 × 5 
minute or 3 × 5 min ischaemic preconditioning protocols, in 
the presence or absence of melatonin (50 µM), followed by 
20 minutes global ischaemia and 30 minutes reperfusion. 
Use was also made of sodium nitroprusside (100 µM), a 
nitric oxide (NO) donor and preconditioning mimetic. Using 
functional recovery as the endpoint, melatonin abolished the 
cardioprotective effects of a multi-cycle (3 × 5 min) precon-
ditioning protocol, while having no effect on a one-cycle 
(1 × 5 min) protocol or SNP (1 × 5 or 3 × 5 min) precondi-
tioning.
The results suggest that free radicals play an important 
role in the cardioprotection induced by a multi-cycle ischae-
mic preconditioning protocol and that this process could be 
attenuated by a potent scavenger such as melatonin.
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Melatonin, the chief secretory product of the pineal gland, 
is a direct scavenger of free radicals and has indirect anti-
oxidant effects due to its stimulation of the expression and 
activity of anti-oxidative enzymes such as glutathione perox-
idase.1,2 The crucial role of free radicals in the pathophysiol-
ogy of the ischaemic heart is well established. Therefore, it is 
not surprising that melatonin has been shown to be a power-
ful cardioprotective agent: melatonin reduces infarct size,3,4 
improves functional recovery of the working rat heart5,6 and 
reduces arrhythmias after coronary artery ligation.7,8 These 
cardioprotective actions of melatonin have been attributed 
largely to its free radical-scavenging properties,5,9,10 although 
a recent study demonstrated that the melatonin receptor is 
also involved.6
Although it is generally accepted that free radicals can 
be detrimental to biological tissues, it has recently been 
discovered that reactive oxygen species (ROS) can function 
as signaling molecules.11 In particular, ROS have been shown 
to play a triggering role in ischaemic preconditioning, the 
phenomenon whereby exposure of a heart to one or more 
short episodes of ischaemia leads to protection against a 
subsequent long period of ischaemia. For example, a precon-
ditioning protocol of 4 × 5 min ischaemia is associated with 
a significant loss of glutathione, while administration of N-
acetylcysteine, an anti-oxidant, blocks the protective effects 
of preconditioning.12 
It has recently been shown13,14 that opening of mito-
chondrial KATP channels by P1075 or diazoxide triggers the 
preconditioning state by generating mitochondrial ROS. 
Conversely, blocking P1075-induced ROS production by 
either glibenclamide or 5-hydroxydecanoate completely 
reverses P1075 anti-infarct effects.13 The triggering action of 
ROS was further confirmed by the finding that its genera-
tion by compounds such as bradykinin15 or SNAP16 mimics 
ischaemic preconditioning.
In view of the above, the question arose whether mela-
tonin, because of its free radical-scavenging actions, will 
affect the beneficial actions of ischaemic preconditioning. 
The aim of the present study was, therefore, to establish 
whether melatonin: (1) has a detrimental effect on either a 
one-cycle or multi-cycle ischaemic preconditioning proto-
col, and (2) will affect the cardioprotective effects of NO, a 
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powerful preconditioning mimetic. In view of its cardiopro-
tective effects when present during reperfusion,6 melatonin 
was added during the preconditioning protocol only, before 
the onset of sustained ischaemia.
Materials and methods
Male Wistar rats weighing 220 to 250 g were used in all 
experiments. Before anaesthesia (30 mg pentobarbital, ip), 
rats were allowed free access to food and water. The project 
was approved by the ethical committee of the Faculty of 
Health Sciences, University of Stellenbosch and conformed 
to the Guide for the Care and Use of Laboratory Animals.17 
Melatonin and sodium nitroprusside were obtained from 
Sigma Chemical Co. All other reagents were of Analar grade 
and obtained from Merck, Cape Town.
Perfusion technique
After removal and arrest in ice-cold saline, the heart was 
mounted via the aorta onto the aortic cannula and perfused 
with Krebs-Henseleit buffer (composition in mM: NaCl 119, 
KCl 4.74, CaCl2 1.25, MgSO4 0.6, Na2SO4 0.59, KH2PO4 
1.79, NaHCO3 24.9, glucose 10) which was oxygenated with 
95% O2, 5% CO2 at 37°C. Hearts were initially perfused 
in a non-recirculating manner at 100 cm H2O to stabilise, 
followed by atrial perfusion (preload 15 cm H2O, afterload 
100 cm H2O). 
Myocardial temperature was thermostatically control-
led by inserting a temperature probe into the pulmonary 
artery. Global ischaemia was induced by reducing flow to 
zero. Temperature during global ischaemia was maintained 
constant at 36.5°C by surrounding the heart with a water-
jacket. Aortic and coronary flows were measured manu-
ally, while aortic pressure and heart rate were monitored 
using a Viggo-Spectramed pressure transducer connected 
to a computer. Total work performance (pressure power 1 
kinetic power) developed by the heart was calculated by the 
formulae of Kannengieser et al.18 Measurements of coronary 
and aortic flow rates, heart rate and peak systolic pressure 
were made before and after ischaemia.
Perfusion protocols (Fig. 1)
● Non-preconditioned hearts (non-PC): hearts were stabi-
lised for 60 min, followed by 20 min global ischaemia 
and 30 min reperfusion.
● Ischaemic preconditioned hearts (IPC): two groups were 
studied:
– 1 × 5 min IPC: hearts were stabilised for 50 min, 
followed by 5 min global ischaemia and 5 min reper-
fusion. Hearts were then subjected to ischaemia and 
reperfusion as described for non-PC hearts.
– 3 × 5 min IPC: hearts were stabilised for 30 min 
followed by three episodes of 5 min global ischaemia, 
interspersed with 5 min reperfusion. Hearts were then 
subjected to ischaemia and reperfusion as described 
above.
● Melatonin-treated ischaemic preconditioned hearts: two 
groups were studied:
– 1 × 5 min IPC 1 melatonin: hearts were stabilised 
for 35 min, followed by administration of melatonin 
(50 µM) for 5 min, 5 min global ischaemia, 5 min 
reperfusion in the presence of melatonin (50 µM) 
and 10 min reperfusion in the absence of melatonin. 
This was followed by ischaemia and reperfusion as 
described above.
– 3 × 5 min IPC 1 melatonin: hearts were stabilised 
for 25 min, followed by administration of melatonin 
(50 µM) for 5 min, three episodes of 5-min global 
ischaemia, interspersed with 5 min reperfusion in the 
presence of melatonin (50 µM), followed by a 10-
min washout period (in absence of melatonin) before 
subjecting hearts to 20 min global ischaemia and 30 
min reperfusion.
● NO-preconditioned hearts (NO-PC): two groups were 
studied.
– 1 × 5 min NO-PC: hearts were stabilised for 50 min, 
followed by administration of sodium nitroprusside 
(SNP) (100 µM) for 5 min and 5 min washout. Hearts 
were then subjected to ischaemia and reperfusion as 
described for non-PC hearts.
– 3 × 5 min NO-PC: hearts were stabilised for 30 min,
Fig. 1. Perfusion protocols. Abbreviations: PC: pre-
conditioning, R: reperfusion, Mel: melatonin, SNP: 
sodium nitroprusside.
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 followed by three 5-min administrations of SNP 
(100 µM), interspersed by 5 min reperfusion. Hearts 
were then subjected to ischaemia and reperfusion as 
described above.
● Melatonin-treated NO-preconditioned hearts: two groups 
were studied.
– 1 × 5 min NO-PC 1 melatonin: hearts were stabilised 
for 40 min, followed by administration of melatonin 
(50 µM) for 10 min, the last 5 min of which SNP 
(100 µM) was added, followed by 5 min washout. 
Hearts were subjected to ischaemia and reperfusion 
as described above.
– 3 × 5 min NO-PC 1 melatonin: hearts were stabilised 
for 20 min, followed by 5-min administrations of 
melatonin (50 µM), followed by three 5-min admin-
istrations of SNP (100 µM) and melatonin (50 µM), 
interspersed by 5-min perfusions in the presence of 
melatonin alone. Hearts were then subjected to a 
10-min washout period, followed by ischaemia and 
reperfusion as described above.
● Melatonin controls: hearts were stabilised for 25 min. 
Melatonin (50 µM) was then administered for three 5-
min periods, interspersed by 5-min reperfusions without 
melatonin and followed by a 10-min washout. Hearts 
were then subjected to 20 min ischaemia and reperfusion 
as described above.
Statistics
Results are expressed as means (± SEM). Multiple compar-
isons were analysed by one-way analyses of variance 
(ANOVA) and the Bonferroni correction was applied as post 
hoc test. P-values < 0.05 were considered significant.
Results
Effect of melatonin on ischaemic precondition-
ing-induced cardioprotection 
Non-preconditioned hearts subjected to 20 min global 
ischaemia showed a significant reduction in aortic flow, 
cardiac output, PSP, heart rate and total work performed 
during reperfusion. Melatonin per se, when administered for 
3 × 5 min followed by 10 min washout before the onset of 
global ischaemia had no effect on functional recovery during 
reperfusion and values similar to those of non-precondi-
tioned hearts were obtained. Preconditioning with 1 × 5 min 
or 3 × 5 min global ischaemia improved functional recovery 
during reperfusion to a similar extent. For example, aortic 
output during reperfusion averaged 19.1 ± 2.1 and 19.07 
± 1.6 ml/min, respectively, compared to 6.3 ± 1.7 ml/min 
in non-preconditioned hearts (a mean increase of 203%). 
Similarly, total work performance was improved by 76 and 
88% by 1 × 5 min and 3 × 5 min preconditioning protocols, 
respectively (Table I).
Melatonin, when administered before and after 1 × 5 min 
ischaemic preconditioning had no effect on the beneficial 
effects of this preconditioning protocol. However, melatonin 
administered before and during a multi-cycle precondition-
ing protocol (3 × 5 min), completely abolished the beneficial 
effect of ischaemic preconditioning and the values obtained 
were similar to those observed in non-preconditioned hearts. 
In addition, heart rate was significantly lower in melatonin-
treated 3 × 5 min preconditioned hearts than in the corre-
sponding 3 × 5 min preconditioned hearts (Table I).
TABLE I. EFFECT OF MELATONIN (50 µM) ON ISCHAEMIC PRECONDITIONED  
CARDIOPROTECTION AFTER 20 MIN GLOBAL ISCHAEMIA
 
 
Coronary flow 
rate (ml/min)
 
Aortic  
output 
(ml/min)
 
Cardiac  
output 
(ml/min)
Peak  
systolic  
pressure 
(mmHg)
 
 
Heart rate 
(beats/min)
 
 
Total work 
(mW)
Before ischaemia (control values) (58)
15.7 ± 0.2 41.6 ± 0.6 57.3 ± 0.7 100.5 ± 0.8 258 ± 4 13.11 ± 0.2
During reperfusion
Non-preconditioned (13) 11.3 ± 0.8 6.3 ± 1.7 17.5 ± 1.9 77.8 ± 3.5 214 ± 12 3.57 ± 0.54
Non-preconditioned  
1 melatonin (9)
12.8 ± 1.0 7.8 ± 1.8 19.8 ± 2.6 82.6 ± 2.9 222 ± 7 3.71 ± 0.56
Preconditioned  
(1 × 5 min) (8)
12.8 ± 0.7 19.1 ± 2.1*1 31.9 ± 2.3*1 87.1 ± 1.1 251 ± 9 6.28 ± 0.51*1
Preconditioned  
(3 3 5 min) (13)
13.2 ± 0.7 19.07 ± 1.6*1 31.2 ± 1.8*1 87.9 ± 1.2 254 ± 9 6.72 ± 0.45*1
Preconditioned  
(1 × 5 min)  
1 melatonin (7)
13.7 ± 0.6 13.3 ± 3.1 27.0 ± 3.0 86.6 ± 1.5 261 ± 9 5.62 ± 0.54
Preconditioned  
1 (3 × 5 min)  
melatonin (8)
9.1 ± 2.7 7.1 ± 2.9** 16.2 ± 6.11** 53.5 ± 15.7**1 149 ± 44** 3.11 ± 0.99**
Numbers in parentheses indicate number of hearts
*p < 0.01 vs non-preconditioned; 1p < 0.05 vs non-preconditioned 1 melatonin;  
**p < 0.01 vs preconditioned 3 × 5 min.
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Effect of melatonin on SNP-induced  
cardioprotection 
Pharmacological preconditioning with SNP, a NO donor, for 
1 × 5 min or 3 × 5 min before the onset of sustained ischae-
mia also caused a significant improvement in cardiac output 
(54 and 58% respectively). Total work was also significantly 
improved (55%) in the case of 3 × 5 min SNP. Interestingly, 
administration of melatonin before and during precondition-
ing with SNP further augmented the beneficial effects of 
the NO donor regardless of the protocol used, although not 
to a significant extent. However, with both protocols, the 
coronary flow rate, aortic output, cardiac output, peak systo-
lic pressure and total work were significantly higher in the 
presence of melatonin, compared with those of non-precon-
ditioned hearts (Table II).
Discussion
To study the effects of melatonin on ischaemic precondition-
ing, melatonin was used at a pharmacological dose (50 µM). 
This concentration has been shown to be cardioprotective in 
the perfused rat heart, while 25 µM was found to be ineffec-
tive.6 Although most workers5,6 used melatonin at pharmaco-
logical doses, it has also been shown to be cardioprotective 
at physiological doses in in vivo studies.7,8
The powerful cardioprotective actions of melatonin have 
been largely attributed to its free radical-scavenging abili-
ties.5,9,10 However, this particular property of melatonin could 
also have adverse actions in certain circumstances, in view of 
the triggering role of free radicals in ischaemic precondition-
ing. The results obtained in our study show that melatonin 
does indeed affect the outcome of ischaemic precondition-
ing, albeit dependent on the protocol used: it had no effect on 
the outcome of a one-cycle preconditioning protocol, while 
causing a significant inhibition of the beneficial effects of a 
three-cycle preconditioning protocol (Table 1).
These results are rather difficult to interpret, since the 
cardioprotection, using functional recovery during reper-
fusion as endpoint, was similar in one- and three-cycle 
preconditioning protocols (Table I). Although a few other 
studies could also not demonstrate differences between one 
or more preconditioning cycles in rabbits,19,20 these findings 
are in contrast to most other previous studies evaluating the 
effect of the number of cycles. For example, a multi-cycle 
preconditioning protocol has been found to be more effective 
than a one-cycle protocol in rats21,22 and pigs,23 using infarct 
size as endpoint. It is also possible that the endpoint used 
(infarct size versus functional recovery) played a role in the 
above discrepancies, since we have previously shown that 
infarct size is a more sensitive indicator of cardioprotection 
than functional recovery.24
The finding that melatonin is able to block a multi-cycle, 
but not a single-cycle preconditioning protocol is surprising, 
in view of other studies where it was found that the latter 
was more susceptible to pharmacological manipulation than 
a multi-cycle protocol. It was suggested that when precon-
ditioning is induced with multiple cycles, the cumulative 
dose of mediators released, and therefore alterations in 
downstream signal transduction pathways may be much 
greater than those achieved in a single cycle.21 Therefore, 
blockade of a single pathway or mechanism of protection 
may be insufficient to block protection induced by a multi-
cycle protocol.
A possible explanation for the inability of melatonin to 
block a single-cycle preconditioning protocol is that free 
radical generation is not an important trigger after only one 
episode of ischaemia. Our data suggest that free radical 
generation becomes a more important trigger during a three-
cycle protocol. Sandhu and coworkers21 also suggested that 
data obtained with pharmacological inhibitors in multi-cycle 
protocols reveal only those factors that are non-redundant 
and, therefore, important in the preconditioning process. The 
significance of free radicals in multi-cycle precondition-
ing protocols has been demonstrated in several studies (for 
example, see reference 12).
The ability of melatonin to block ischaemic precondition-
ing via free radical scavenging was further evaluated using 
the preconditioning mimetic nitric oxide (NO). Despite 
TABLE II. EFFECT OF MELATONIN (50 µM) ON SNP-INDUCED  
CARDIOPROTECTION AFTER 20 MIN GLOBAL ISCHAEMIA
 
Coronary flow 
rate (ml/min)
 
Aortic output 
(ml/min)
 
Cardiac output 
(ml/min)
Peak 
systolic pressure 
(mmHg)
 
Heart rate 
(beats/min)
 
Total work 
(mW)
Before ischaemia (control values) (39)
16.0 ± 0.3 40.7 ± 0.6 56.7 ± 0.8 103.3 ± 1.1 256 ± 5 13.32 ± 0.28
During reperfusion
Non-preconditioned 
(13)
11.3 ± 0.8 6.3 ± 1.7 17.5 ± 1.9 77.8 ± 3.5 214 ± 12 3.57 ± 0.54
SNP (1 × 5 min) (7) 13.2 ± 0.7 13.7 ± 3.0 26.9 ± 3.21 88.7 ± 3.0 245 ± 9 5.44 ± 0.78
SNP (3 × 5 min) (6) 13.6 ± 0.6 14.1 ± 1.3 27.7 ± 1.11 89.7 ± 1.6 229 ± 13 5.55 ± 0.311
SNP (1 × 5 min)  
1 melatonin (6)
15.6 ± 0.6* 19.0 ± 2.5* 34.9 ± 2.82* 92.3 ± 3.21 234 ± 14 7.32 ± 0.871
SNP (3 × 5 min)  
1 melatonin (7)
15.4 ± 0.4* 15.4 ± 2.4* 30.79 ± 2.74* 91.7 ± 2.21 235 ± 11 6.37 ± 0.651
SNP: 100 µM, administered 1 × 5 min or 3 × 5 min. Numbers in parentheses indicate number of hearts
*p < 0.01 vs non-preconditioned; 1p < 0.05 vs non-preconditioned.
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initial controversial results, the role of NO in precondition-
ing and cardioprotection is being increasingly recognised, 
and a variety of NO donors have been used (for summary, 
see reference 25), including sodium nitroprusside.6,26 The 
data in Table II show that SNP pretreatment significantly 
improved cardiac output and work performance after expo-
sure to 20 min global ischaemia. Interestingly, melatonin, 
when administered prior to and simultaneous with SNP, 
tended to improve rather than block functional recovery. 
The beneficial cardioprotective actions of NO include 
activation of guanylyl cyclase, generation of cyclic guano-
sine monophosphate (cGMP), activation of protein kinase G 
(PKG) and opening of the mitochondrial KATP channels.25 
The results obtained in this study (Table II) suggest that 
the amounts of NO generated by SNP completely override 
the scavenging abilities of melatonin, or else that mela-
tonin is not capable of scavenging this particular free radical. 
However, it has been shown that melatonin is capable of 
detoxifying NO.27,28 
Melatonin has also been suggested to interact with a 
molecule derived from NO, possibly peroxynitrite. The 
results obtained in the present study could not show any 
evidence of NO scavenging by melatonin, since no deleteri-
ous effects on SNP-induced cardioprotection were observed. 
The interrelationship between melatonin and a NO donor in 
the perfused heart model needs to be further evaluated.
The results obtained with melatonin are in agreement 
with those obtained by other workers using free radical 
scavengers. For example, administration of ascorbic acid in 
pigs abolished the beneficial effects of preconditioning on 
infarct size,29 while mercaptopropionyl-glycine diminished 
diazoxide-induced preconditioning.30 As far as we know, the 
effect of melatonin on ischaemic preconditioning has previ-
ously been studied by one group only.31 Using rabbits, mela-
tonin (50 mg/kg) was found to have no effect on ischaemic 
preconditioning-induced reduction in infarct size, despite a 
reduction in lipid peroxidation and increase in superoxide 
dismutase (SOD) activity. 
There are several reasons for the differences between our 
results and those obtained by Andreadou et al.31 For example, 
animal species (rat vs rabbit), model (in vitro vs in vivo), 
preconditioning protocol (1 × 5, 3 × 5 min vs 2 × 5 min), 
period of ischaemia (20 vs 30 min), and severity of ischae-
mia (global vs coronary artery ligation) could all affect the 
outcome.
Finally, our results show that melatonin, at a concentra-
tion of 50 µM, is capable of abolishing the cardioprotective 
actions of a multi-cycle ischaemic preconditioning protocol, 
probably by virtue of its free radical-scavenging abilities. 
Melatonin may also exert its effects via its powerful anti-
adrenergic actions,32 which could attenuate the generation of 
cAMP, one of the triggers of ischaemic preconditioning.33 In 
addition, we have previously shown that the cardioprotection 
induced by melatonin during reperfusion could be abolished 
by luzindole, a melatonin receptor blocker.6 However, the 
role of the melatonin receptor in abolishing preconditioning 
remains to be established.
In summary, melatonin’s actions on the perfused heart 
are dependent on the time of administration. If added during 
reperfusion only, melatonin is cardioprotective, while when 
administered before and during an ischaemic precondition-
ing protocol, it abolishes protection.
We acknowledge the National Research Foundation, South Africa and the 
Research Council of Norway for financial support.
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